IBI310+IBI308 + IBI308 + High-dose recombinant interferon a-2B
Phase 3Terminated 3 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Acral Melanoma That Has Been Removed by Surgery
Conditions
Acral Melanoma That Has Been Removed by Surgery
Trial Timeline
Apr 17, 2020 → Feb 28, 2023
NCT ID
NCT04277663About IBI310+IBI308 + IBI308 + High-dose recombinant interferon a-2B
IBI310+IBI308 + IBI308 + High-dose recombinant interferon a-2B is a phase 3 stage product being developed by Innovent Biologics for Acral Melanoma That Has Been Removed by Surgery. The current trial status is terminated. This product is registered under clinical trial identifier NCT04277663. Target conditions include Acral Melanoma That Has Been Removed by Surgery.
What happened to similar drugs?
0 of 1 similar drugs in Acral Melanoma That Has Been Removed by Surgery were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04277663 | Phase 3 | Terminated |
Competing Products
7 competing products in Acral Melanoma That Has Been Removed by Surgery
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Nivolumab + Ipilimumab | Bristol Myers Squibb | Phase 2 | 27 |
| VX-548 + Placebo | Vertex Pharmaceuticals | Phase 2 | 35 |
| BIIB074 + Placebo | Biogen | Phase 2 | 32 |
| CNV1014802 + Placebo | Biogen | Phase 2 | 32 |
| BIIB074 | Biogen | Phase 2 | 24 |
| SP-102 + Placebo | Scilex Holding | Phase 3 | 30 |
| SP-102 | Scilex Holding | Phase 2 | 25 |